Role of the Combination of Cyclin-Dependent Kinase Inhibitors (CDKI) and Radiotherapy (RT) in the Treatment of Metastatic Breast Cancer (MBC): Advantages and Risks in Clinical Practice

MLA

Ambrogio Gagliano, et al. “Role of the Combination of Cyclin-Dependent Kinase Inhibitors (CDKI) and Radiotherapy (RT) in the Treatment of Metastatic Breast Cancer (MBC): Advantages and Risks in Clinical Practice.” Frontiers in Oncology, vol. 11, June 2021. EBSCOhost, https://doi.org/10.3389/fonc.2021.643155.

APA

Ambrogio Gagliano, Angela Prestifilippo, Ornella Cantale, Gianluca Ferini, Giacomo Fisichella, Paolo Fontana, Dorotea Sciacca, & Dario Giuffrida. (2021). Role of the Combination of Cyclin-Dependent Kinase Inhibitors (CDKI) and Radiotherapy (RT) in the Treatment of Metastatic Breast Cancer (MBC): Advantages and Risks in Clinical Practice. Frontiers in Oncology, 11. https://doi.org/10.3389/fonc.2021.643155

Chicago

Ambrogio Gagliano, Angela Prestifilippo, Ornella Cantale, Gianluca Ferini, Giacomo Fisichella, Paolo Fontana, Dorotea Sciacca, and Dario Giuffrida. 2021. “Role of the Combination of Cyclin-Dependent Kinase Inhibitors (CDKI) and Radiotherapy (RT) in the Treatment of Metastatic Breast Cancer (MBC): Advantages and Risks in Clinical Practice.” Frontiers in Oncology 11 (June). doi:10.3389/fonc.2021.643155.